Nexstim Oyj: Nexstim Receives an NBT System Order from a New Therapy Customer in Finland
Therapy Customer in Finland
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received a new NBT System order from a therapy customer in Finland.
This is a new customer for Nexstim and the system will be used to treat Major Depressive Disorder (MDD).
Nexstim s NBT System with SmartFocus nTMS is highly differentiated from other currently available TMS products due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation, and magnitude of the stimulation.
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Savosolar Plc s business review for January–March 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nexstim Oyj: Nexstim Plc Business and Clinical Update Q1 2021 Q1 2021
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces the key highlights of the Company s business and clinical progress during Q1 2021.
CEO Mikko Karvinen s
pdate
Glad to inform that our operational business has had the best start of the year ever while beginning our first full year of executing our renewed strategy. During the first months of 2021, we have continued to invest in the growth of our diagnostic and therapeutic business with the recruitment of two new sales team members to our US organization. At the same time, we are extremely pleased to see that our existing NBS and NBT System customer base has increased the utilisation rate of our installed base to a record level. High utilization of the systems leads into growing levels of high margin recurring revenue, an important element in our profitable growth strategy.
Investegate |Nexstim Oyj Announcements | Nexstim Oyj: Correction to the Invitation to the Annual General Meeting of Nexstim Plc investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.